肺炎不動桿菌治療市場、機會、成長動力、產業趨勢分析與預測，2024-2032

Acinetobacter Pneumonia Therapeutics Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年08月21日 | 出版商:

Global Market Insights Inc. | 英文 160 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2023 年全球肺炎不動桿菌治療市場價值為4.668 億美元，預計2024 年至2032 年將以6.2% 的複合年成長率強勁成長。流行率不斷上升推動的，一種與嚴重院內感染有關的病原體，特別是在免疫功能低下的患者中。這些感染的發生率不斷上升，特別是在重症監護病房（ICU）中，增加了對有效治療方案的需求，進一步推動了市場成長。

不動桿菌肺炎療法專注於專門設計用於對抗不動桿菌屬（尤其是鮑曼不動桿菌）引起的肺炎的藥物和治療方法。這種類型的肺炎在醫院環境中普遍存在，通常對多種抗生素表現出抗藥性，使治療變得複雜。

整個肺炎不動桿菌治療產業根據藥物類別、給藥途徑、年齡層、配銷通路和地區進行分類。

依藥物類別，市場分為幾個藥物類別，包括頭孢菌素類、碳青黴烯類、氟喹諾酮類、甘氨醯環素類、B-內醯胺類抗生素、舒巴坦、氨基糖苷類、多粘菌素類、四環素類、磺胺類等。 2023年，頭孢菌素細分市場以7,070萬美元領先市場。頭孢菌素因其廣譜活性和對不動桿菌屬（包括 MDR 菌株）的有效性而受到青睞。它們的高效、低毒性和多種劑型使其在這一治療領域佔據主導地位。

依給藥途徑，市場分為腸胃外、口服和吸入途徑。 2023 年，腸外給藥佔據了最大的市場佔有率，達到 73.1%。這種方法對於重症患者尤其重要，使其成為醫院環境中的首選。

按年齡層，市場分為老年、成人和兒科細分市場。老年病領域在 2023 年處於領先地位，預計 2024 年至 2032 年將以 6.1% 的複合年成長率成長。全球老齡化人口的不斷增加進一步推動了針對這一人群的專門治療的需求。

依配銷通路分類，市場分為醫院藥房、零售藥房和網路藥房。醫院藥局在 2023 年佔據主導地位，預計到 2032 年將達到 4.441 億美元。它們在管理和分配治療嚴重感染的專用抗生素、確保及時、準確地交付藥物方面發揮著至關重要的作用。

在北美，不動桿菌肺炎治療市場2023年價值為2.247億美元，預計複合年成長率為6.0%。該地區先進的醫療基礎設施、院內感染的高發病率以及對研發的大量投資使其在市場中佔據主導地位。

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 沙烏地阿拉伯
- 南非
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 10 章：公司簡介

AstraZeneca PLC
Basilea Pharmaceutica Ltd.
Bayer AG
GlaxoSmithKline plc
Johnson and Johnson
Merck and Co., Inc.
Novartis AG
Pfizer Inc.
Sanofi S.A.

簡介目錄

Product Code: 10900

The Global Acinetobacter Pneumonia Therapeutics Market was valued at USD 466.8 million in 2023 and is projected to grow at a robust CAGR of 6.2% from 2024 to 2032. This growth is driven by the increasing prevalence of multidrug-resistant (MDR) strains of Acinetobacter baumannii, a pathogen linked to severe hospital-acquired infections, particularly among immunocompromised patients. The rising incidence of these infections, especially in intensive care units (ICUs), has heightened the demand for effective treatment options, further boosting market growth.

Acinetobacter pneumonia therapeutics focuses on drugs and treatments specifically designed to combat pneumonia caused by Acinetobacter species, especially Acinetobacter baumannii. This type of pneumonia, prevalent in hospital settings, often shows resistance to multiple antibiotics, complicating treatment.

The overall Acinetobacter pneumonia therapeutics industry is categorized based on Drug Class, Route of Administration, Age-group, Distribution Channel, and Region.

By Drug Class, the market is categorized into several drug classes, including cephalosporins, carbapenems, fluoroquinolones, glycylcyclines, B-lactam antibiotics, sulbactam, aminoglycosides, polymyxins, tetracyclines, sulfonamides, and others. In 2023, the cephalosporins segment led the market with USD 70.7 million. Cephalosporins are preferred due to their broad-spectrum activity and effectiveness against Acinetobacter species, including MDR strains. Their high efficacy, low toxicity, and various formulations contribute to their dominance in this therapeutic area.

By Route of Administration, the market is segmented into parenteral, oral, and inhalation routes. Parenteral administration held the largest market share of 73.1% in 2023. This route is favored for severe infections like Acinetobacter pneumonia because it delivers medications directly into the bloodstream for rapid action. This method is especially crucial for critically ill patients, making it the preferred choice in hospital settings.

By Age Group, the market is divided into geriatric, adult, and pediatric segments. The geriatric segment led in 2023 and is expected to grow at a CAGR of 6.1% from 2024 to 2032. The elderly are particularly susceptible to Acinetobacter infections due to age-related immune decline and comorbidities. The rising global aging population further drives the demand for specialized treatments for this demographic.

By Distribution Channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacies dominated in 2023 and are anticipated to reach USD 444.1 million by 2032. They play a crucial role in managing and dispensing specialized antibiotics for severe infections, ensuring timely and accurate delivery of medications.

In North America, the Acinetobacter pneumonia therapeutics market was valued at USD 224.7 million in 2023 and is expected to grow at a CAGR of 6.0%. The region's advanced healthcare infrastructure, high prevalence of hospital-acquired infections, and substantial investments in R&D contribute to its dominant position in the market.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising prevalence of Acinetobacter infections
  - 3.2.1.2 Advancements in drug development
  - 3.2.1.3 Growing awareness and diagnosis rates
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 High cost of treatment
  - 3.2.2.2 Side effects and toxicity
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Cephalosporins
5.3 Carbapenem
5.4 Fluoroquinolone
5.5 Glycylcycline
5.6 B-Lactam antibiotics
5.7 Sulbactam
5.8 Aminoglycoside
5.9 Polymyxins
5.10 Tetracycline
5.11 Sulfonamide
5.12 Other drug classes

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Parenteral
6.3 Oral
6.4 Inhalation

Chapter 7 Market Estimates and Forecast, By Age-group, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Geriatric
7.3 Adult
7.4 Pediatric

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Hospital pharmacies
8.3 Retail pharmacies
8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 The Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 Saudi Arabia
- 9.6.2 South Africa
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa